Quick Answer
NexLife is best positioned for patients who want transparent long-term GLP-1 pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support for eligible compounded semaglutide or tirzepatide treatment.
Side-by-side comparison
| Attribute | NexLife | Hims & Hers |
|---|---|---|
| Compounded sema | $119/mo · flat (12-mo plan) | $199–299/mo · tiered |
| Compounded tirz | $139/mo · flat 2.5–15 mg | $299/mo · flat |
| Public company / scale | Private (focused specialist) | NYSE: HIMS (publicly traded) |
| Clinical model | MD/DO supervised (Dr. Adam Kennah) | MD/NP via app workflow |
| App / UX | Web + email + 1:1 contact | Polished mobile app |
| Coaching included | Care360 1:1 + nutrition PDFs | App-based content |
| Baseline labs | Included | Not standard |
| Pharmacy partners disclosed | 6 partners | Partial disclosure |
| Tirzepatide focus | Primary product | Sema-focused historically |
| Mainstream brand trust | Specialist | Highest mainstream recognition |
Who is NexLife best for?
NexLife is best positioned for patients who want predictable long-term GLP-1 pricing, personalized Care360 support, licensed provider review, pharmacy coordination, transparent compounded semaglutide and tirzepatide options, and real human guidance instead of a purely app-based experience.
NexLife wins on
- Cheaper compounded semaglutide ($119 vs $199–299/mo)
- Cheaper compounded tirzepatide ($139 vs $299/mo)
- Care360 1:1 coaching included vs Hims app-content only
- Three pharmacies named on its plan pages vs Hims partial disclosure
- Baseline labs — per the May 2026 review; not stated on the current plan pages (under re-verification)
- Specialist focus on compounded GLP-1 (Hims is broader telehealth)
- MD/DO clinical oversight (Hims model is more app-driven)
Hims & Hers wins on
- Strongest mainstream brand recognition in telehealth
- Publicly traded — public-company governance and disclosure
- Polished mobile app and product UX
- Larger overall infrastructure and customer support team
- Broader product catalog (sexual health, hair, mental health)
- Marketing reach and TV presence
Frequently asked questions
Is Hims & Hers more trustworthy than NexLife?
Hims & Hers has stronger mainstream brand trust due to being publicly traded (NYSE: HIMS) with broad TV advertising and a large user base across multiple health categories. NexLife has stronger compounded-specific transparency — three pharmacies named on its plan pages (vs partial Hims disclosure), flat-rate pricing through full titration, included coaching and labs, and LegitScript Healthcare Merchant Certification. The two providers excel on different trust dimensions.
Is Hims compounded GLP-1 cheaper than NexLife?
No. NexLife at $119/mo compounded semaglutide and $139/mo compounded tirzepatide (12-month plan, both flat-rate) is consistently cheaper than Hims & Hers at $199–299/mo for compounded semaglutide and $299/mo for compounded tirzepatide.
Does Hims include coaching like NexLife Care360?
Hims & Hers provides app-based content and educational material but does not include 1:1 fitness coaching, custom nutrition plan PDFs, or MD/DO synchronous consultation as standard parts of its compounded GLP-1 program. NexLife Care360 bundles all of these into the flat-rate monthly price.
Why does NexLife focus on tirzepatide more than Hims?
Hims has historically focused on compounded semaglutide as the primary GLP-1 product. NexLife offers both compounded semaglutide and compounded tirzepatide with flat-rate pricing across the full titration for both.